2-((cyclohexylmethyl)amino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one | 870711-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2-((cyclohexylmethyl)amino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one
• 英文别名: 2-(cyclohexylmethylamino)-5-methyl-5-propylthiazol-4(5H)-one；2-[(Cyclohexylmethyl)amino]-5-methyl-5-propyl-4,5-dihydro-1,3-thiazol-4-one；2-(cyclohexylmethylimino)-5-methyl-5-propyl-1,3-thiazolidin-4-one
• CAS: 870711-09-4
• 化学式: C₁₄H₂₄N₂OS
• 分子量: 268.423
• InChiKey: QFAZDDSXCQFUSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴-2-甲基-2-丙基乙酸乙酯 、 环己基甲基硫脲 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-((cyclohexylmethyl)amino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one
  参考文献：
  名称：

  2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme−Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice

  摘要：

  11 beta-Hydroxy steroid dehydrogenase type 1 (11 beta-HSD1) has attracted considerable attention during the past few years as a potential target for the treatment of diseases associated with metabolic syndrome. In our ongoing work on 11-HSD1 inhibitors, a series of new 2-amino-1,3-thiazol-4(5H)-ones were explored. By inserting various cycloalkylamines at the 2-position and alkyl groups or spirocycloalkyl groups at the 5-position of the thiazolone, several potent 11 beta-HSD1 inhibitors were identified. An X-ray cocrystal structure of human 11 beta-HSD1 with compound 6d (K-i = 28 nM) revealed a large lipophilic pocket accessible by substitution off the 2-position of the thiazolone. To increase potency, analogues were prepared with larger lipophilic groups at this position. One of these compounds, the 3-noradamantyl analogue 8b, was a potent inhibitor of human 11 beta-HSD 1 (K-i = 3 nM) and also inhibited 11 beta-HSD1 activity in lean C57BI/6 mice when evaluated in an ex vivo adipose and liver cortisone to cortisol conversion assay.

  DOI：

  10.1021/jm701551j

文献信息

• Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
  申请人：Henriksson Martin

  公开号：US20080045503A1

  公开（公告）日：2008-02-21

  The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

  本发明涉及具有式（I）、（II）、（III）或（IV）的化合物：其中R1、R2、R3、R4、R5、R6、R7、X和Z如本文所定义的，并且还涉及包括该化合物的制药组合物，以及使用该化合物治疗与人类11-β-羟基类固醇脱氢酶1型酶相关的疾病的方法，以及制备作用于人类11-β-羟基类固醇脱氢酶1型酶的药物的方法。
• Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1
  申请人：Henriksson Martin

  公开号：US20070281938A1

  公开（公告）日：2007-12-06

  The present invention relates to compounds with the formula (I) wherein R 1 , R 2 , R 3 , R 4 , and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

  本发明涉及化合物式（I），其中R1、R2、R3、R4和Z的定义如本文所述，以及包含该化合物的制药组合物，以及该化合物在医学上的使用和用于制备对人类11-β-羟基类固醇脱氢酶1型酶起作用的药物。
• INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1
  申请人：Henriksson Martin

  公开号：US20110082107A1

  公开（公告）日：2011-04-07

  The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

  本发明涉及具有式（I），（II），（III）或（IV）的化合物：其中R1，R2，R3，R4，R5，R6，R7，X和Z如本文所定义，并且还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗与人类11-β-羟基类固醇脱氢酶1型酶相关的疾病的方法，以及用于制备对人类11-β-羟基类固醇脱氢酶1型酶起作用的药物的方法。
• US7253196B2
  申请人：——

  公开号：US7253196B2

  公开（公告）日：2007-08-07
• US7807700B2
  申请人：——

  公开号：US7807700B2

  公开（公告）日：2010-10-05